Press release
Systemic Lupus Erythematosus Clinical Trial Pipeline Analysis: 120+ Key Companies Shaping the Future of SLE Therapeutics | DelveInsight
Key takeaways from the SLE Clinical Trial Landscape Report
• DelveInsight's SLE pipeline report depicts a robust space with 120+ active players working to develop 140+ pipeline therapies for SLE treatment.
• Key SLE companies such as Biogen, Zenas Biopharma, Otsuka Pharmaceutical, AbbVie, Synthekine, Beijing Mabworks Biotech Co., Ltd., and others
• Promising SLE pipeline therapies in various stages of development include BIIB059, Obexelimab, VIS171, SYNCAR-001, MIL62, and others
Request a sample and discover the recent advances in SLE treatment drugs https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight?utm_source=linkedin&utm_medium=promotion&utm_campaign=kspr
What is Systemic Lupus Erythematosus?
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disorder characterized by systemic inflammation that can affect multiple organs, including the skin, joints, kidneys, lungs, heart, and brain. It primarily occurs in women of reproductive age and often follows a relapsing-remitting course, with periods of disease flare-ups and remission. The disease's pathology involves immune complex deposition, vasculitis, and vasculopathy, with lupus nephritis being a major cause of morbidity and mortality. The symptoms include fatigue, fever, weight loss, joint pain, muscle weakness, and multi-organ involvement. The treatment involves NSAIDs, antimalarials, corticosteroids, immunosuppressants, and biologics. The causes are associated with genetic, environmental, and hormonal factors. The diagnosis is based on clinical examination, laboratory tests, and imaging.
Emerging SLE Drug Profiles
BIIB059: Biogen
BIIB059 is a humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2) and is being investigated for the treatment of Systemic Lupus Erythematosus (SLE). It reduces inflammatory cytokine production, including type-I interferons, by targeting plasmacytoid dendritic cells. The therapy is currently in Phase III clinical development for SLE.
Obexelimab: Zenas Biopharma
Obexelimab is a monoclonal antibody targeting B-cell pathways and Fc gamma receptor IIB, designed to inhibit B-cell activation and reduce autoimmune responses. The therapy is currently in Phase II clinical development for the treatment of Systemic Lupus Erythematosus (SLE).
Learn more about the novel and emerging SLE pipeline therapies https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight?utm_source=linkedin&utm_medium=promotion&utm_campaign=kspr
Recent Developments in the SLE Clinical Trial Landscape
• In March 2026, Johnson & Johnson announced that its investigational therapy nipocalimab received Fast Track designation from the US Food and Drug Administration (FDA) for the treatment of adults with Systemic Lupus Erythematosus (SLE), and the company is actively enrolling patients in a Phase III clinical study.
• In February 2026, Lupus Research Alliance and SLEuro announced collaboration initiatives to advance research and showcase the latest innovations in Systemic Lupus Erythematosus (SLE) treatment and clinical development.
• In January 2026, Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug therapy, nipocalimab, met its primary endpoint and multiple key secondary and exploratory endpoints in adults with Systemic Lupus Erythematosus (SLE).
• In January 2026, AstraZeneca reported positive results from a Phase III TULIP-SC clinical trial, showing a statistically significant and clinically meaningful reduction in disease activity with the subcutaneous self-administration of anifrolumab in adults with Systemic Lupus Erythematosus (SLE).
• In October 2025, Biogen Inc. announced presentations evaluating dapirolizumab pegol (DZP), demonstrating efficacy across multiple endpoints including disease activity, flares, fatigue, joint pain, and quality of life in Systemic Lupus Erythematosus (SLE).
Scope of the SLE Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Parenteral, Subcutaneous
• Therapeutics Assessment By Molecule Type: Monoclonal antibody, Small molecule, Peptide, Polymer, Recombinant fusion proteins, and others
• Key SLE Companies: Biogen, Zenas Biopharma, Otsuka Pharmaceutical, AbbVie, Synthekine, Beijing Mabworks Biotech Co., Ltd., and others
• Key SLE Pipeline Therapies: BIIB059, Obexelimab, VIS171, SYNCAR-001, MIL62, and others
Dive deep into rich insights for new drugs for SLE treatment, visit https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight?utm_source=linkedin&utm_medium=promotion&utm_campaign=kspr
Table of Contents
1. SLE Pipeline Report Introduction
2. SLE Pipeline Report Executive Summary
3. SLE Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. SLE Pipeline Therapeutics
6. SLE Pipeline: Late Stage Products (Pre-registration)
7. SLE Pipeline: Late Stage Products (Phase III)
8. SLE Pipeline: Mid Stage Products (Phase II)
9. SLE Pipeline: Early Stage Products (Phase I)
10. SLE Pipeline Therapeutics Assessment
11. Inactive Products in the SLE Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products in the SLE Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
For further information on the SLE pipeline therapeutics, reach out https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight?utm_source=linkedin&utm_medium=promotion&utm_campaign=kspr
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Systemic Lupus Erythematosus Clinical Trial Pipeline Analysis: 120+ Key Companies Shaping the Future of SLE Therapeutics | DelveInsight here
News-ID: 4499173 • Views: …
More Releases from DelveIinsight Business Research
Chronic Rhinosinusitis with Nasal Polyps Market Size in the 7MM is Projected to …
The market dynamics for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) therapies is witnessing significant growth driven by the rising diagnosed prevalent patient pool, increasing awareness of persistent sinonasal symptoms, improving diagnosis rates, and expanding adoption of biologic therapies. Growing demand for targeted therapies with durable disease control, advancements in endoscopic interventions, and increasing use of corticosteroids and monoclonal antibodies are further supporting market expansion. Additionally, the launch of emerging therapies…
Charcot-Marie-Tooth Market Size in the 7MM is Projected to Enhance at a Signific …
The market dynamics for Charcot-Marie-Tooth (CMT) therapies is witnessing significant growth driven by the rising diagnosed patient population, increasing awareness of inherited neuropathies, expanding access to genetic testing, and growing demand for disease-modifying treatment options. Improved disease recognition, better supportive care pathways, and increasing clinical research activity are further supporting market expansion. Additionally, the launch of emerging therapies such as Govorestat (Applied Therapeutics), Ignaseclant/NMD670 (NMD Pharma), IFB-088 (InFlectis BioSciences), and…
Acute Myeloid Leukemia Market Size in the 7MM is Projected to Grow at a Signific …
The market dynamics for Acute Myeloid Leukemia is witnessing significant growth driven by the rising incidence of AML with aging populations, increasing adoption of precision medicine supported by genetic mutation testing, and growing demand for targeted and less intensive treatment options for unfit and relapsed/refractory patients. Additionally, the launch of emerging therapies such as RVU120 (Ryvu Therapeutics SA), Galinpepimut S and SLS009 (SELLAS Life Sciences), IPN60340 (Ipsen), and others will…
Steroid Refractory Acute GvHD Market Size in the 7MM is Projected to Enhance at …
The market dynamics for Steroid Refractory Acute Graft-Versus-Host Disease (SR-aGvHD) is witnessing significant growth driven by the rising number of allogeneic hematopoietic stem cell transplants, increasing incidence of acute GvHD cases, and higher rates of steroid-refractory disease following first-line corticosteroid treatment. Growing demand for rapid-acting targeted therapies, improved disease recognition, and expanding use of advanced cell-based and immunomodulatory treatments are further supporting market expansion. Additionally, the launch of emerging therapies…
More Releases for SLE
Systemic Lupus Erythematosus (SLE) Market Detailed Industry Report Analysis 2025 …
Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease where the immune system attacks multiple organ systems, including skin, joints, kidneys, and blood vessels. It is often unpredictable, with flare-ups and remissions that complicate management. Symptoms range from fatigue and skin rashes to life-threatening organ damage.
While conventional treatments such as corticosteroids, antimalarials, and immunosuppressants remain central, recent years have seen significant advances with biologics, targeted therapies, and precision medicine approaches.…
Systemic lupus erythematosus (SLE) Market: Analysis and Segment Forecasts To 20 …
Systemic lupus erythematosus (lupus) is an autoimmune disease which is characterized by inflammation of tissue in the body. Immune response is directed toward the body’s own cells, resulting in acute or chronic inflammation. Symptoms of lupus are general and hence often mistaken with symptoms of other diseases. This results in unnoticed progression of disease in the body. The disease is more common in women and usually affects individuals in the…
Systemic lupus erythematosus (SLE) Market Research Report : Forecast 2025
In terms of geography, North America accounts for the dominant share in terms of revenue owing to advancements in the treatment of systemic lupus erythematosus and rising awareness among people about the disease. Europe accounts for the second largest market in terms of revenue due to high incidence rate of SLE and increase in research activities in the field of systemic lupus erythematosus. The Asia Pacific market is also witnessing…
Systemic lupus erythematosus (SLE) Market Report by Regional Analysis : forecast …
Systemic lupus erythematosus (lupus) is an autoimmune disease which is characterized by inflammation of tissue in the body. Immune response is directed toward the body’s own cells, resulting in acute or chronic inflammation. Symptoms of lupus are general and hence often mistaken with symptoms of other diseases. This results in unnoticed progression of disease in the body. The disease is more common in women and usually affects individuals in the…
Global Resuscitation Ventilators Market 2017 : Eternity, SIRIUSMED, Siare & SLE
The survey report by Market Research Store is an overview of the global Resuscitation Ventilators market. It covers all the recent trends including key developments in the global market in present and in future. Analyses of the global Resuscitation Ventilators market trends along with the projections of CAGRs (compound annual growth rates) are provided in the research report.
Further, an evaluation of the history of the global market and the basic…
Global Respiratory Devices Market-SLE Ltd, Teijin Pharma, Resmed, Weinmann
Global Respiratory Devices Market report 2017 is an in-depth research on the current situation of the Respiratory Devices industry.
The Scope of the Respiratory Devices research report:
The Global Respiratory Devices Market primarily includes a basic overview of the Respiratory Devices industry. It also includes Respiratory Devices definitions, classifications and applications. It segments the market by applications, types, regions, competitive players and also analyzes Respiratory Devices market size, business share and Respiratory…
